Search

Your search keyword '"Shoumariyeh, Khalid"' showing total 233 results

Search Constraints

Start Over You searched for: Author "Shoumariyeh, Khalid" Remove constraint Author: "Shoumariyeh, Khalid"
233 results on '"Shoumariyeh, Khalid"'

Search Results

1. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease

2. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

3. Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model

4. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

5. GPRC5C drives branched-chain amino acid metabolism in leukemogenesis

6. Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

7. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

8. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis

9. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

10. Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.

11. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

12. Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies

13. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry

14. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin

15. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

17. Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure

18. Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model

19. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

22. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia

23. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

24. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

25. Community-driven development of a modified progression-free survival ratio for precision oncology

26. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

27. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response

28. Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation

29. Mast cell leukemia:clinical and molecular features and survival outcomes of patients in the ECNM Registry

30. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

31. Elevated RIPK3 correlates with disease burden in myelofibrosis

32. Patient‐derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphoma

33. Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

34. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

35. MPN-334 Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis (AdvSM): Results From Part 1 of the Phase 2 Apex Trial

36. Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis (AdvSM): Results From Part 1 of the Phase 2 Apex Trial

37. Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany

38. Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies

39. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

40. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

41. CD49d Shapes B Cell Receptor Responsiveness and Tissue Distribution in an Aggressive Chronic Lymphocytic Leukemia Murine Model

42. Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

43. Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

44. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

45. Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis

46. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis

47. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans

48. Blastic transformation of BCR‐ABL1 positive chronic myeloid leukaemia through acquisition of CBFB‐MYH11 and mutant KIT

49. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification

50. International prognostic scoring system for mastocytosis (IPSM) : a retrospective cohort study

Catalog

Books, media, physical & digital resources